- Home
- RMTI vs GRML Comparison
RMTI vs GRML Comparison
Compare RMTI & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMTI | GRML |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 29.2M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RMTI | GRML |
|---|---|---|
| Price | $7.91 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 20.9K | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,258,000.00 | N/A |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.16 |
| 52 Week High | $8.50 | $11.66 |
Technical Indicators
Market Signals| Indicator | RMTI | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 49.40 |
| Support Level | $7.28 | $0.20 |
| Resistance Level | $8.50 | $11.66 |
| Average True Range (ATR) | 0.41 | 0.50 |
| MACD | -0.11 | -0.33 |
| Stochastic Oscillator | 46.72 | 4.51 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.